Antimicrobial Agents Practice Questions

Q: Which of the following combinations does not show synergistic action?

Penicillin plus tetracycline. ***Penicillin plus tetracycline*** - This combination is generally **antagonistic** or **indifferent**, not synergistic. Penicillin is a cell wall synthesis inhibitor that works best on actively growing bacteria, while tetracycline is a bacteriostatic protein synthesis inhibitor that can reduce bacterial growth, thereby diminishing penicillin's effect. - The combination is usually avoided as the **bacteriostatic action of tetracycline** can counteract the **bactericidal action of penicillin**, leading to reduced efficacy, especially in infections requiring rapid bacterial clearance. *Penicillin plus sulfonamide* - This combination can show synergism in some contexts, particularly as sulfonamides inhibit **folate synthesis**, while penicillin inhibits **cell wall synthesis**. - While not a classic synergistic pair for all infections, their mechanisms of action are distinct, and they can sometimes be used together, although specific synergistic effects are more limited compared to other pairs. *Streptomycin plus penicillin* - This is a classic example of **synergistic action**, particularly in conditions like **enterococcal endocarditis**. - Penicillin damages the bacterial cell wall, allowing **streptomycin** (an aminoglycoside) to more easily penetrate the cell and act on ribosomal targets, leading to enhanced bactericidal effect. *Rifampicin plus dapsone* - This combination is a cornerstone of **multi-drug therapy for leprosy**, demonstrating clear synergy against *Mycobacterium leprae*. - **Rifampicin** inhibits bacterial RNA synthesis, and **dapsone** inhibits folate synthesis, attacking different essential bacterial pathways which, when combined, are more effective and reduce the development of resistance.

Q: Which drug is linked to hypertrophic pyloric stenosis in infants?

Erythromycin. ***Erythromycin*** - Studies have shown an association between infantile exposure to **erythromycin** and an increased risk of developing **hypertrophic pyloric stenosis**. - This risk is particularly noted when erythromycin is administered during the **first two weeks of life**, possibly due to its potent motilin receptor agonism. *Tetracycline* - **Tetracycline** is known for causing **teeth discoloration** and **bone growth retardation** in infants and children. - It is generally contraindicated in pediatric populations due to these significant side effects, but it is not linked to pyloric stenosis. *Ampicillin* - **Ampicillin** is a penicillin antibiotic commonly used in infants for bacterial infections. - While it can cause side effects like **rashes** and **diarrhea**, there is no established link to hypertrophic pyloric stenosis. *Rifampicin* - **Rifampicin** is an antibiotic primarily used for treating tuberculosis. - Its main side effects include **hepatotoxicity** and **red-orange discoloration of body fluids**, but it has no known association with hypertrophic pyloric stenosis.

Q: Which antitubercular drug makes the patient non-infective the earliest?

Isoniazid (INH). ***Isoniazid (INH)*** - **Isoniazid** renders TB patients **non-infectious the fastest**, typically within **2-3 days** of starting treatment - It has the most **rapid bactericidal effect** against actively multiplying extracellular **Mycobacterium tuberculosis**, which are the primary organisms responsible for transmission - INH works by inhibiting **mycolic acid synthesis**, disrupting the bacterial cell wall of rapidly dividing bacilli - This makes it the most critical drug for **early infection control** and reducing community transmission *Rifampin* - While **rifampin** is highly bactericidal and has excellent sterilizing activity, it takes **slightly longer** than INH to render patients non-infectious - Rifampin is particularly effective against **semi-dormant organisms** and intracellular bacilli - It is the most important drug for **preventing relapse** and shortening treatment duration, but INH acts faster in reducing infectivity *Ethambutol* - **Ethambutol** is primarily **bacteriostatic**, inhibiting arabinosyl transferase and interfering with cell wall synthesis - Its main role is to **prevent emergence of drug resistance** rather than rapidly reducing bacterial load - Has minimal impact on early infectivity reduction *Pyrazinamide* - **Pyrazinamide** is most effective against **semi-dormant bacilli** within macrophages and in acidic environments - Its **sterilizing activity** helps shorten overall treatment duration but does not contribute significantly to rapid reduction in infectivity - Works slowly and is not bactericidal against actively multiplying extracellular organisms

Q: Which of the following is the longest acting carbapenem?

Ertapenem. ***Ertapenem*** - **Ertapenem** has the **longest half-life** among the carbapenems, allowing for once-daily dosing. - Its prolonged action is due to its **chemical structure**, which provides high protein binding and reduced renal clearance compared to other carbapenems. *Imipenem* - **Imipenem** has a **relatively short half-life** and requires co-administration with cilastatin to prevent its renal metabolism by dehydropeptidase-1. - Its short duration of action necessitates **frequent dosing**, typically every 6 to 8 hours. *Meropenem* - **Meropenem** has a **shorter half-life** than ertapenem, generally requiring dosing every 8 hours. - Although it does not require cilastatin, its pharmacokinetic profile is not as extended as ertapenem's. *Doripenem* - **Doripenem** also has a **shorter half-life** than ertapenem, necessitating administration every 8 hours. - Its spectrum of activity is similar to meropenem, but it does not offer the same extended duration of action.

Q: In patients undergoing INH therapy, which group is least likely to develop neuropathy?

Fast acetylators. ***Fast acetylators*** - **Fast acetylators** metabolize INH more quickly, leading to lower systemic drug levels and thus a reduced risk of adverse effects like neuropathy. - Neuropathy associated with INH is primarily due to **pyridoxine (vitamin B6) depletion**, which is less pronounced if the drug is rapidly cleared. *Having malnutrition* - **Malnutrition** often involves deficiencies in essential vitamins, including vitamin B6, which is crucial for preventing INH-induced neuropathy. - Patients with poor nutritional status are at a **higher risk** of developing neuropathy during INH therapy due to pre-existing vitamin B6 depletion. *Alcoholics* - **Alcoholism** is strongly associated with deficiencies in various B vitamins, particularly **pyridoxine (vitamin B6)**, due to poor diet and impaired absorption. - This pre-existing deficiency makes alcoholics **highly susceptible** to INH-induced neuropathy. *Vitamin B complex deficiency* - A **deficiency in vitamin B complex**, especially pyridoxine (B6), is a known risk factor for INH-induced neuropathy. - Isoniazid interferes with **pyridoxine metabolism**, and those with pre-existing deficiency are more vulnerable to this adverse effect.

Q: Which of the following is a primary use of Levamisole?

Antihelminthic. ***Antihelminthic*** - Levamisole is **primarily classified as an antihelminthic drug**, used to treat parasitic worm infections. - It acts as a **nicotinic receptor agonist** in nematodes, causing spastic paralysis of the worms, leading to their expulsion. - It was historically used in humans for treating ascariasis and hookworm infections, and is still used in **veterinary medicine** for deworming livestock. - This is its **primary pharmacological classification** in standard medical textbooks. *Immunomodulator* - Levamisole does have **immunomodulatory properties** that were discovered secondary to its antihelminthic use. - It was used as **adjuvant therapy in colon cancer** (with 5-FU) to enhance immune response. - However, this is a **secondary use**, not its primary classification, and has been largely discontinued due to severe side effects like agranulocytosis. *Immunostimulant* - While levamisole can stimulate certain aspects of cell-mediated immunity, this overlaps with its immunomodulatory effects. - This is **not its primary pharmacological classification** - it remains primarily an antihelminthic agent. *None of the options* - This is incorrect because **antihelminthic** is clearly the primary and correct classification of levamisole in pharmacology. - Its antihelminthic action was its original and primary therapeutic application.

Q: Which of the following conditions is not associated with an increased risk of neuropathy caused by Isoniazid (INH)?

Hyperthyroidism. ***Hyperthyroidism*** - **Hyperthyroidism** is not typically associated with an increased risk of isoniazid-induced neuropathy. The neuropathy due to INH is primarily linked to **pyridoxine (vitamin B6) deficiency**. - While hyperthyroidism can cause its own set of neurological symptoms, it does not directly impair pyridoxine metabolism or exacerbate INH's neurotoxic effects. *Uremia* - **Uremia** (renal failure) can increase the risk of INH-induced neuropathy due to impaired drug excretion, leading to higher plasma concentrations of INH and its metabolites. - Patients with uremia often have compromised nutritional status and may experience vitamin deficiencies, further contributing to pyridoxine depletion. *Diabetes mellitus* - **Diabetes mellitus** is a significant risk factor for INH-induced neuropathy because it is an independent cause of **peripheral neuropathy** itself, making patients more susceptible to additional nerve damage. - Diabetic patients may also have altered pyridoxine metabolism or suboptimal nutritional intake, predisposing them to INH toxicity. *Poor nutrition* - **Poor nutrition**, particularly malabsorption or inadequate dietary intake, directly contributes to **pyridoxine (vitamin B6) deficiency**. - Isoniazid's mechanism of neurotoxicity involves interfering with pyridoxine metabolism, so pre-existing deficiency significantly increases the risk of neuropathy.

Q: Which of the following is not excreted by the kidney?

Moxifloxacin. ***Moxifloxacin*** - Moxifloxacin is primarily metabolized in the **liver** and excreted through bile and feces. - This characteristic makes it a suitable choice for patients with significant **renal impairment** as dose adjustments are generally not required. *Ciprofloxacin* - Ciprofloxacin is predominantly excreted by the **kidneys** through both glomerular filtration and tubular secretion. - Dose adjustments are crucial in patients with **renal dysfunction** to prevent accumulation and toxicity. *Ofloxacin* - Ofloxacin is largely excreted unchanged in the **urine**, making renal excretion its primary elimination pathway. - **Dose reduction** is necessary for patients with impaired renal function. *Levofloxacin* - Levofloxacin is primarily eliminated via **renal excretion**, with a significant portion appearing in the urine as unmetabolized drug. - Patients with **kidney disease** require appropriate dose adjustments.

Q: Emtricitabine is a/an:

Nucleoside reverse transcriptase inhibitor (NRTI). ***Nucleoside reverse transcriptase inhibitor (NRTI)*** - **Emtricitabine** is a synthetic nucleoside analog that inhibits the activity of HIV-1 **reverse transcriptase**, an enzyme essential for viral replication. - It works by being phosphorylated to its active triphosphate form, which then competes with natural deoxycytidine triphosphate for incorporation into the viral DNA, leading to **chain termination**. *Alkylating agent* - **Alkylating agents** are a class of antineoplastic drugs that work by adding an alkyl group to DNA, forming a covalent bond that interferes with DNA replication and transcription. - They are primarily used in **cancer chemotherapy**, not as antiviral agents for HIV. *Mitotic inhibitor* - **Mitotic inhibitors** are drugs that interfere with cell division (mitosis) by targeting microtubules, either inhibiting their polymerization or depolymerization. - These agents are also used in **cancer treatment** to prevent rapidly dividing cells from completing mitosis. *None of the options* - This option is incorrect because **emtricitabine** clearly belongs to the class of **nucleoside reverse transcriptase inhibitors**.

Q: Thymidine is responsible for resistance to which antibiotic ?

Sulfonamide. ***Sulfonamide*** - **Thymidine** can contribute to **sulfonamide resistance** because sulfonamides interfere with **folate metabolism** and the subsequent synthesis of purines and pyrimidines, including thymidine. - An excess of thymidine can bypass the metabolic block caused by sulfonamides, allowing bacteria to continue DNA synthesis and grow. *Erythromycin* - **Erythromycin** resistance is primarily mediated by **methylation of ribosomal RNA**, which prevents the antibiotic from binding to the 50S ribosomal subunit. - It does not directly involve thymidine or the folate synthesis pathway. *Tetracycline* - Resistance to **tetracyclines** is commonly due to **efflux pumps** that actively pump the drug out of the bacterial cell or **ribosomal protection proteins** that prevent tetracycline binding. - Thymidine production or metabolism is not a mechanism of tetracycline resistance. *Nitrofurantoin* - **Nitrofurantoin** resistance typically involves **mutations** in bacterial enzymes (like **nitrofuran reductase**) that are responsible for activating the drug into its active form. - These mutations prevent the drug from becoming bactericidal, and thymidine does not play a role in this mechanism.

Question 1

Which of the following combinations does not show synergistic action?

Accepted Answer

Penicillin plus tetracycline

Answer

Streptomycin plus penicillin

Answer

Rifampicin plus dapsone

Answer

Penicillin plus sulfonamide

Question 2

Which drug is linked to hypertrophic pyloric stenosis in infants?

Accepted Answer

Erythromycin

Answer

Ampicillin

Answer

Rifampicin

Answer

Tetracycline

Question 3

Which antitubercular drug makes the patient non-infective the earliest?

Accepted Answer

Isoniazid (INH)

Answer

Ethambutol

Answer

Pyrazinamide

Answer

Rifampin

Question 4

Which of the following is the longest acting carbapenem?

Accepted Answer

Ertapenem

Answer

Imipenem

Answer

Meropenem

Answer

Doripenem

Question 5

In patients undergoing INH therapy, which group is least likely to develop neuropathy?

Accepted Answer

Fast acetylators

Answer

Having malnutrition

Answer

Alcoholics

Answer

Vitamin B complex deficiency

Question 6

Which of the following is a primary use of Levamisole?

Accepted Answer

Antihelminthic

Answer

Immunostimulant

Answer

None of the options

Answer

Immunomodulator

Question 7

Which of the following conditions is not associated with an increased risk of neuropathy caused by Isoniazid (INH)?

Accepted Answer

Hyperthyroidism

Answer

Uremia

Answer

Diabetes mellitus

Answer

Poor nutrition

Question 8

Which of the following is not excreted by the kidney?

Accepted Answer

Moxifloxacin

Answer

Ciprofloxacin

Answer

Ofloxacin

Answer

Levofloxacin

Question 9

Emtricitabine is a/an:

Accepted Answer

Nucleoside reverse transcriptase inhibitor (NRTI)

Answer

Alkylating agent

Answer

Mitotic inhibitor

Answer

None of the options

Question 10

Thymidine is responsible for resistance to which antibiotic ?

Accepted Answer

Sulfonamide

Answer

Erythromycin

Answer

Tetracycline

Answer

Nitrofurantoin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?